Novel synthetic benzimidazole-derived oligosaccharide, M3BIM, prevents ex vivo platelet aggregation and in vivo thromboembolism
详细信息 查看全文
- 作者：Ting-Lin Yen ; Ming-Ping Wu ; Chi-Li Chung ; Wen-Bin Yang…
- 关键词：Arterial thrombosis ; Benzimidazole ; derived oligosaccharide ; Cerebral infarction ; Platelet aggregation
- 刊名：Journal of Biomedical Science
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：23
- 期：1
- 全文大小：1,682 KB
- 刊物类别：Biomedical and Life Sciences
- 刊物主题：Biomedicine
Biomedicine - 出版者：Springer Netherlands
- ISSN：1423-0127
文摘
Background Thrombus formation, a phenomenon primarily related to increased platelet activation, plays a key role in cardiovascular and cerebrovascular diseases. Although the established antiplatelet agents, such as aspirin and clopidogrel, have been shown to be beneficial in treating thromboembolic diseases, they have considerable limitations. Hence, the development of more effective and safe antithrombotic agents is necessary to satisfy a substantial unmet clinical need. In recent years, the favorable properties of imidazole-related drugs have prompted medicinal chemists to synthesize numerous novel therapeutic agents. The chemical structure of the benzimidazole backbone has proven antiplatelet properties. Moreover, synthetic oligosaccharides have exhibited antiplatelet properties. Therefore, we developed a new aldo-benzimidazole-derived oligosaccharide compound, M3BIM, for achieving a stronger antiplatelet effect than the drugs which are being used in clinical aspects. We investigated the effects of M3BIM on platelet activation ex vivo and its antithrombotic activity in vivo.